Novel APOL1 Inhibitors for Treating Kidney Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1230 Peachtree Street NE, Suite 3100, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2020 Oct 20;11(12):2352-2353. doi: 10.1021/acsmedchemlett.0c00531. eCollection 2020 Dec 10.
Abstract
摘要
相似文献
1
Novel APOL1 Inhibitors for Treating Kidney Diseases.用于治疗肾脏疾病的新型载脂蛋白L1（APOL1）抑制剂
ACS Med Chem Lett. 2020 Oct 20;11(12):2352-2353. doi: 10.1021/acsmedchemlett.0c00531. eCollection 2020 Dec 10.
2
Optimal management of HIV- positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction "R3" Trial): protocol and study design.在尼日利亚，针对有肾脏疾病风险的 HIV 阳性成年人的最佳管理（肾脏风险降低“R3”试验）：方案和研究设计。
Trials. 2019 Jun 10;20(1):341. doi: 10.1186/s13063-019-3436-y.
3
ApoL1 induces kidney inflammation through RIG-I/NF-κB activation.载脂蛋白 L1 通过 RIG-I/NF-κB 激活诱导肾脏炎症。
Biochem Biophys Res Commun. 2020 Jun 25;527(2):466-473. doi: 10.1016/j.bbrc.2020.04.054. Epub 2020 Apr 24.
4
APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease.APOL1 风险变异可预测 HIV 相关肾脏疾病的组织病理学和进展为终末期肾病。
J Am Soc Nephrol. 2012 Feb;23(2):343-50. doi: 10.1681/ASN.2011060562. Epub 2011 Dec 1.
5
APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.肾细胞中的载脂蛋白L1 G1型诱导肥大并加速细胞死亡。
J Am Soc Nephrol. 2017 Apr;28(4):1106-1116. doi: 10.1681/ASN.2016050550. Epub 2016 Nov 18.
6
APOL1 localization in normal kidney and nondiabetic kidney disease.APOL1 在正常肾脏和非糖尿病肾脏疾病中的定位。
J Am Soc Nephrol. 2011 Nov;22(11):2119-28. doi: 10.1681/ASN.2011010069. Epub 2011 Oct 13.
7
APOL1 and kidney cell function.APOL1 与肾脏细胞功能。
Am J Physiol Renal Physiol. 2019 Aug 1;317(2):F463-F477. doi: 10.1152/ajprenal.00233.2019. Epub 2019 Jun 26.
8
Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.携带 G2/G2APOL1 高危基因型的新型人足细胞细胞模型。
Cells. 2021 Jul 28;10(8):1914. doi: 10.3390/cells10081914.
9
APOL1 toxin, innate immunity, and kidney injury.载脂蛋白L1毒素、固有免疫与肾损伤。
Kidney Int. 2015 Jul;88(1):28-34. doi: 10.1038/ki.2015.109. Epub 2015 Apr 8.
10
The Cell Biology of APOL1.APOL1 的细胞生物学。
Semin Nephrol. 2017 Nov;37(6):538-545. doi: 10.1016/j.semnephrol.2017.07.007.
引用本文的文献
1
Molecular Dynamic Simulation Reveals Structure Differences in Variants and Implication in Pathogenesis of Chronic Kidney Disease.分子动力学模拟揭示了慢性肾病发病机制中变异体的结构差异及其意义。
Genes (Basel). 2022 Aug 16;13(8):1460. doi: 10.3390/genes13081460.
2
Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases.使用脂质修饰剂治疗肾小球疾病。
J Pers Med. 2021 Aug 21;11(8):820. doi: 10.3390/jpm11080820.
本文引用的文献
1
Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.局灶节段性肾小球硬化症：现状与临床视角。
Nephron. 2020;144(9):413-427. doi: 10.1159/000508099. Epub 2020 Jul 28.
2
Approach to Diagnosis and Management of Primary Glomerular Diseases Due to Podocytopathies in Adults: Core Curriculum 2020.成人足细胞病相关原发性肾小球疾病的诊断和治疗方法：2020 年核心课程。
Am J Kidney Dis. 2020 Jun;75(6):955-964. doi: 10.1053/j.ajkd.2019.12.019. Epub 2020 Apr 21.
3
Apolipoprotein E-related glomerular disorders.载脂蛋白E相关肾小球疾病
Kidney Int. 2020 Feb;97(2):279-288. doi: 10.1016/j.kint.2019.10.031. Epub 2019 Nov 22.
4
The Impact of APOL1 on Chronic Kidney Disease and Hypertension.APOL1 对慢性肾脏病和高血压的影响。
Adv Chronic Kidney Dis. 2019 Mar;26(2):131-136. doi: 10.1053/j.ackd.2019.01.003.
Zotero 插件